INDOCO REMEDIES LTD.
INDOCO · General/Diversified · NSE
₹240
Current Market Price
Fair Value (DCF)
₹257
Discount to FV
+7.2%
Updated just now
YieldIQ Score
36/100
Piotroski F-Score
4/9
Economic Moat
None
Confidence
28%
ROE
-10.1%
Debt/Equity
1.16
WACC
11.1%
Market Cap
₹2,208 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
7.0%
Return on capital employed
EV / EBITDA
18.1×
Enterprise multiple
Debt / EBITDA
7.7×
Leverage vs earnings
Interest Coverage
-0.2×
EBIT covers interest
Current Ratio
1.24×
Short-term liquidity
Asset Turnover
0.76×
Revenue per ₹ of assets
Revenue CAGR (3Y)
3.0%
3-year revenue growth
Revenue CAGR (5Y)
7.6%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹239.57
Bear case
Margin of Safety -21.1%
Implied upside -17.4%
Base case
Margin of Safety +6.3%
Implied upside +6.7%
Bull case
Margin of Safety +29.2%
Implied upside +41.3%
Ratio Trends
INDOCO · last 9 annual periods
ROE
-10.1%
ROCE
7.0%
Operating Margin
—
Debt / Equity
1.16×
PE
21.1×
EV / EBITDA
18.1×
Historical Financials
INDOCO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1504 Cr | ₹1640 Cr | ₹1788 Cr | ₹1641 Cr | ₹1793 Cr | +4.5% |
| EBITDA | ₹330 Cr | ₹287 Cr | ₹263 Cr | ₹106 Cr | ₹142 Cr | -19.0% |
| EBIT | ₹251 Cr | ₹218 Cr | ₹174 Cr | — | — | -8.8% |
| PAT | ₹155 Cr | ₹142 Cr | ₹98.5 Cr | ₹-73.7 Cr | ₹-95.2 Cr | — |
| EPS (diluted) | ₹16.80 | ₹15.42 | ₹10.51 | — | — | -11.1% |
| CFO | ₹174 Cr | ₹179 Cr | ₹155 Cr | ₹90.8 Cr | ₹226 Cr | +6.8% |
| CapEx | ₹-125 Cr | ₹-207 Cr | ₹-426 Cr | ₹-258 Cr | ₹-125 Cr | — |
| FCF | ₹48.5 Cr | ₹-28.4 Cr | ₹-271 Cr | ₹-168 Cr | ₹101 Cr | +20.1% |
| Total Assets | ₹1486 Cr | ₹1658 Cr | ₹2145 Cr | ₹2430 Cr | ₹2593 Cr | +14.9% |
| Total Debt | ₹257 Cr | ₹333 Cr | ₹672 Cr | ₹994 Cr | ₹1090 Cr | +43.5% |
| Shareholders' Equity | ₹905 Cr | ₹1028 Cr | ₹1110 Cr | ₹1022 Cr | ₹939 Cr | +0.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
INDOCO vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 WINDLAS WINDLAS | — | — | Pending | 12.1% | — |
MOREPENLAB MOREPENLAB | — | — | Pending | 7.6% | — |
 HIKAL HIKAL | — | — | Pending | -4.1% | — |
SOLARA SOLARA | — | — | Pending | 0.0% | — |
 UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹7.70/sh
Last payout
2025-09-04
₹0.20
Peak payout
₹2.25
Trailing yield
0.08%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. INDOCO REMEDIES LTD. (INDOCO.NS) trades at 239.57 vs a model fair value of 256.90, a gap of 7.2%. Piotroski F-score: 4/9. Moat label: Non...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of INDOCO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for INDOCO →
Compare
Head-to-head with peers
Compare INDOCO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse INDOCONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.